Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
54 Results for "
RAMOS
" in MedChemExpress (MCE) Product Catalog:
Products (54)
54 Results for "RAMOS" in MCE Product Catalog:
Cat. No.: HY-183188
CAS No.: 3097646-97-1
Target:
Research Areas:
Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
7-Methoxy-4H-chromen-4-one-o-carborane is an ER agonist and COX inhibitor with a COX-1 IC50 of 3.0 μM, COX-2 IC50 of 1.0 μM. 7-Methoxy-4H-chromen-4-one-o-carborane can be used for research on antimicrobial, anti-inflammatory, antitumor, neuroprotective, and estrogenic effects .
Cat. No.: HY-182080
CAS No.: 710280-48-1
Target:
Research Areas:
EVs inducer-1 is a release inducer of immunostimulatory extracellular vesicles (EVs). EVs inducer-1 inhibits tubulin polymerization. EVs inducer-1 enhances the release of immunostimulatory EVs by antigen-presenting cells, increases the release of EV particles from dendritic cells, and elevates CD63 reporter gene activity. EVs inducer-1 inhibits the viability of proliferating cells. EVs inducer-1 is applicable for research related to immune regulation .
Cat. No.: HY-181546
Target:
Research Areas:
Ibt-DOX is a BTK inhibitor with an IC50 of 2.89 nM. Ibt-DOX is also a targeted covalent activated chemotherapeutic agent composed of the targeting ligand Ibrutinib (HY-10997), Doxorubicin (DOX) (HY-15142A), α-MAA (HY-W017180), and a linker (HY-Y0892). Ibt-DOX specifically binds to BTK and releases DOX, synergistically achieving BTK inhibition and chemotherapeutic killing, significantly enhancing toxicity against B-cell lymphoma cells and greatly reducing the toxic side effects of DOX on BTK-negative cells. Ibt-DOX can be used in lymphoma-related research .
Cat. No.: HY-185830
Research Areas:
ADC Control Human IgG1-vcMMAE (DAR8) is an antibody-drug conjugate (ADCs), serving as an isotype control for ADC human IgG1-vcMMAE, and inhibits tubulin polymerization. The antibody moiety of ADC Control Human IgG1-vcMMAE (DAR8) is Human IgG1 kappa, Isotype Control (HY-P99001), while the cytotoxic payload and linker moiety are VcMMAE (HY-15575). ADC Control Human IgG1-vcMMAE can be used in cancer-related research .
Cat. No.: HY-186233
Research Areas:
CS-1-174 is a biotin-modified probe derived from KCC-07 (HY-131031), with specific binding activity to enrich MBD2. CS-1-174 captures MBD2 in cell lysates via pull-down by binding streptavidin magnetic beads through its terminal biotin tag. CS-1-174 serves as a functional tool probe in the development of TRACER technology, and is used to verify the target binding ability of MBD2 in tumor cells .
Cat. No.: HY-P992488
Synonyms: ZV0501 Antibody
Research Areas:
Cat. No.: HY-181064
Target:
Research Areas:
FWG-33B is an activator of TRMT112:METTL5 complex with an IC50 value of 0.47 μM. FWG-33B can be used for the research of breast carcinoma, hepatocellular carcinoma, nasopharyngeal carcinoma .
Cat. No.: HY-183187
CAS No.: 3097646-96-0
Target:
Research Areas:
4H-Chromen-4-one-o-carborane is an estrogen receptor (ER) agonist, with an EC50 of 0.9 μM for ERα and an EC50 of 11.1 μM for ERβ. 4H-Chromen-4-one-o-carborane also acts as an inhibitor of COX-1 and COX-2, with an IC50 of 6.6 μM for COX-1 and an IC50 of 17.7 μM for COX-2 .
Cat. No.: HY-187439
Target:
Research Areas:
Truly-4 is a bifunctional Rpn13 PROTAC and CRBN ByeTAC degrader. Degradation of Rpn13 relies on CRBN-mediated E3 ubiquitin ligase activity, while degradation of CRBN itself proceeds via a ByeTAC mechanism of action. Truly-4 induces selective cytotoxicity in hematological cancer cells and solid cancer cells, but not in healthy cells, despite comparable levels of Rpn13 depletion in both cell types. Truly-4 can be used in studies related to B-cell lymphoma and triple-negative breast cancer .
Cat. No.: HY-P992408
Target:
Research Areas:
Cat. No.: HY-181869
CAS No.: 2409674-38-8
Target:
Research Areas:
PROTAC BET Degrader-17 is a potent BET protein PROTAC degrader. By recruiting the VHL E3 ligase, PROTAC BET Degrader-17 specifically degrades BRD2, BRD3 (DC50=0.09 nM) and BRD4 (IC50=4.3 nM). PROTAC BET Degrader-17 exhibits strong anti-tumor activity in acute myeloid leukemia (AML) studies; it not only inhibits cancer cell proliferation, induces cell cycle arrest and apoptosis, but also effectively suppresses tumor growth in xenograft mouse models. PROTAC BET Degrader-17 can be used to explore targeted therapies for acute myeloid leukemia .
Cat. No.: HY-183643
Target:
Research Areas:
RUVBL1/2-IN-1 is an orally active RUVBL1/2 complex inhibitor with an EC50 of 0.012 μM against human targets. RUVBL1/2-IN-1 impairs ATPase-related functions, thereby reducing nuclear MYC protein levels, impairing DNA damage response and inhibiting cancer cell proliferation. In a MYC-dependent Burkitt's lymphoma xenograft model, RUVBL1/2-IN-1 effectively inhibits tumor growth and suppresses the activity of RUVBL1 R117H mutant cells. RUVBL1/2-IN-1 has been applied in research related to MYC-dependent Burkitt's lymphoma .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
